A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

NCT00975767 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
126
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2.

Conditions

Interventions

Sponsor

Mirati Therapeutics Inc.